Pfizer antibiotic may bring re-infections according to a study
Pfizer infectious disease researcher Charles Knirsch said he is skeptical of the paper's conclusion related to natural immunity because the researchers didn't provide evidence to support that finding. He said there is no good way to test to determine whether someone has developed immunity to trachoma. The higher recurrence of infections among a certain group might be explained by geographical location, he said. Other studies, including one on patients in Morocco, showed that treating the entire population with Zithromax almost wipes out the disease, Knirsch said. „The solution isn't to wait 15, 20 years for a vaccine to come along,” Knirsch said. “The solution is to treat 100% of the community and eliminate this blinding disease.”
Pliva d.d., based in Zagreb, Croatia, makes a generic copy of Zithromax, as do Basel, Switzerland-based Novartis AG, and Petah Tikva, Israel-based Teva Pharmaceutical Industries Ltd. Trachoma infects the inside of the eyelid, and scaring builds up over time that makes the eyelashes turn inward. Eventually the eyelashes start scratching the surface of the eye, allowing bacteria to get into the eye and leading to blindness. The study was funded by the New York-based International Trachoma Initiative and the National Institutes of Health in Bethesda, Maryland. (Bloomberg)
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.